{
    "clinical_study": {
        "@rank": "38451", 
        "arm_group": [
            {
                "arm_group_label": "SANGUINATE\u2122", 
                "arm_group_type": "Experimental", 
                "description": "PEG-bHb-CO"
            }, 
            {
                "arm_group_label": "Normal Saline Solution", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Saline Solution"
            }
        ], 
        "brief_summary": {
            "textblock": "Safety assessment of SANGUINATE\u2122 in Healthy Volunteers."
        }, 
        "brief_title": "An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE\u2122 in Healthy Volunteers.", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Drug Safety", 
        "detailed_description": {
            "textblock": "Safety and Pharmacokinetic assessment in ascending doses of SANGUINATE\u2122 in Healthy\n      Volunteers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male Volunteers;\n\n          -  Age \u226518 years and \u226445 years;\n\n          -  BMI \u226520- \u226430 kg/m\u00b2\n\n          -  No clinically significant screening observations\n\n        Exclusion Criteria:\n\n          -  Female volunteers;\n\n          -  Any history of significant cardiac, renal, neurologic, metabolic, pulmonary,\n             gastrointestinal, chronic hepatic disease or any other disease which in the judgment\n             of the Investigator would interfere with the study or confound the results;\n\n          -  History of allergy or major allergic reactions considered to be clinically\n             significant by the Investigator;\n\n          -  Any screening assessment determined to be clinically significant by the Investigator;\n\n          -  Donate blood within 60 days of screening or otherwise experienced blood loss >250 mL\n             within the same period;"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847222", 
            "org_study_id": "SGHV-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "SANGUINATE\u2122", 
                "description": "PEG-bHb-CO", 
                "intervention_name": "SANGUINATE\u2122", 
                "intervention_type": "Biological", 
                "other_name": "PEG-bHb-CO"
            }, 
            {
                "arm_group_label": "Normal Saline Solution", 
                "description": "Placebo", 
                "intervention_name": "Normal Saline Solution", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 3, 2013", 
        "location": {
            "contact": {
                "email": "b_brenner@rambam.health.gov", 
                "last_name": "Benjamin Brenner, MD", 
                "phone": "972 4 8543520"
            }, 
            "facility": {
                "address": {
                    "city": "Haifa", 
                    "country": "Israel"
                }, 
                "name": "Rambam Health Care Facility"
            }, 
            "investigator": {
                "last_name": "Benjamin Brenner, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE\u2122 in Healthy Volunteers.", 
        "overall_official": {
            "affiliation": "Rambam Health Care Facility", 
            "last_name": "Benjamin Brenner, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse events of SANGUINATE\u2122", 
            "measure": "Number of participants with adverse events as a measure of safety and tolerability.", 
            "safety_issue": "Yes", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847222"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Prolong Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Prolong Pharmaceuticals", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}